This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Helicos BioSciences Corporation Announces Appointment Of Ivan Trifunovich As President And CEO

Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that its Board of Directors has appointed Dr. Ivan Trifunovich as the company’s President and Chief Executive Officer. Dr. Trifunovich has served as a senior consultant to the Helicos Board of Directors and was elected to serve as Executive Chairman of the Board of Helicos on September 15, 2010. Ron Lowy, who stepped in as CEO at the board’s request will return to his role as a board member. Helicos today also announced the launch of a technology licensing program for its Single Molecule Sequencing Platform.

Commenting on behalf of the Helicos Board of Directors, company’s co-founder Stan Lapidus said, “As a result of hard work by Ron and the Helicos management team the HeliScope sequencing platform has continued to advance in performance and applications, while the Company’s intellectual property portfolio has been significantly strengthened. We appreciate Ron’s leadership during the past two years and look forward to his continued contributions on the Board.”

“I am excited to take over the leadership of Helicos during this critical time as we introduce our technology licensing program,” said Dr. Trifunovich. “We intend to create the maximum value from our strong intellectual property portfolio in single molecule sequencing, which we consider to be an absolute requirement for anyone competing in the rapidly growing next-generation, single molecule sequencing market.”

“Helicos was the first to invent and market single molecule sequencing technology and has established a comprehensive patent estate with the earliest priority dates in the field,” continued Dr. Trifunovich. “We are pleased to announce that our foundational patents will be made available to encourage broad commercialization of genetic sequencing-by-synthesis and other related technologies. We plan to leverage this broad intellectual property estate that covers all sequencing-by-synthesis methods through licensing, partnering and enforcement strategies. Our plan is to vigorously defend our IP rights.” The Helicos licensing portfolio includes approximately 48 issued patents and 90 applications.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs